arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

download Export Data

Immunovant, Inc.

IMVT

$37.27 ▲ +0.11 (+0.30%) at close

9 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Immunovant, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.8B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-2.23 ↗

Trailing P/E —

Price / Book 8.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-505.61M

↓ -22.2% —

FCF / Share Free cash flow per share

$-2.23

↑ +10.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
EPS Growth YoY (%)	-1.5% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-45.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-9.9% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-19.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-17.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-22.2% Weak ↑ Weak Improving Year-over-year change in net income	-59.6% Weak ↓ Weak Declining Year-over-year change in net income	-22.9% Weak ↑ Weak Improving Year-over-year change in net income	-34.6% Weak ↑ Weak Improving Year-over-year change in net income	-45.9% Weak ↑ Weak Improving Year-over-year change in net income	-61.8% Weak Weak Year-over-year change in net income	-132.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	10.1% Fair ↑ Fair Improving Year-over-year change in free cash flow	-59.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	-1.5% Weak ↑ Weak Improving Year-over-year change in free cash flow	-57.8% Weak Weak Year-over-year change in free cash flow	-1.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 2 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Return on Capital (%) (%)	—	—	-38.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-52.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-30.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-59.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-495%)	-58.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-490%)	-42.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-380%)	-58.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-488%)	-33.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-322%)	-27.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-283%)	-70.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-570%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Net Debt (USD)	$-902.11M	$-713.97M	$-635.37M	$-376.53M	$-493.82M	$-400.15M	$-100.57M	$-6.99M	—

📊 What does each share earn? 5 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-2.77	$-2.73	$-1.88	$-1.71	$-1.43	$-1.22	—	—	—
Free Cash Flow per Share (USD)	$-2.23	$-2.48	$-1.55	$-1.53	$-0.97	$-0.95	—	—	—
Book Value per Share (USD)	$4.18	$4.16	$4.24	$2.78	$4.03	$4.00	$1.72	$0.19	—
Tangible Book Value per Share (USD)	$4.18	$4.16	$4.24	$2.78	$4.03	$4.00	$1.72	$0.19	—
Basic Weighted Avg Shares (shares)	182.42M	151.57M	138.10M	123.08M	109.68M	87.76M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Working Capital (USD)	$844.40M	$698.89M	$617.16M	$361.04M	$468.41M	$390.24M	$93.76M	—	—
Total Equity (USD)	$852.59M	$707.45M	$617.76M	$362.49M	$469.82M	$391.48M	$94.07M	$7.34M	$-1.50M

📋 What is driving earnings? 3 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Depreciation Expense (USD)	$409.00K	$377.00K	$231.00K	$193.00K	$126.00K	$65.00K	$21.00K	$10.00K	—
Net Income, GAAP (USD)	$-505.61M	$-413.84M	$-259.34M	$-210.96M	$-156.73M	$-107.43M	$-66.39M	$-28.60M	—
Operating Cash Flow (USD)	$-407.31M	$-375.87M	$-214.23M	$-188.19M	$-106.11M	$-83.33M	$-53.36M	$-28.55M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 34 quarters

Immunovant, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IMVT with peers